Last reviewed · How we verify
Antimuscarinics
At a glance
| Generic name | Antimuscarinics |
|---|---|
| Sponsor | Samsung Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of 4 Methods of Eye Drops for Pupil Dilation in Diabetic Patients (NA)
- Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
- A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation (PHASE4)
- Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial (NA)
- Outcomes of Urinary Incontinence Treatment in Primary Care: APP Co-Management and Electronic Consult (NA)
- A Practice-Based Intervention To Improve Care for a Diverse Population Of Women With Urinary Incontinence (NA)
- A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia (PHASE2)
- An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antimuscarinics CI brief — competitive landscape report
- Antimuscarinics updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI